No Data
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Zhao Lingzhi plans to reduce her shareholding by no more than 0.4 million shares.
Gelonghui reported on December 20 that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that Ms. Zhao Lingzhi plans to reduce her shareholding in the company through a centralized bidding method by no more than 400,000 shares (which is no more than 0.0316% of the company's total share capital, and no more than 25% of her personal holdings) within three months after 15 trading days from the date of this announcement. If there are any changes in rights, such as the distribution of dividends, issuance of bonus shares, capitalization of reserves, issuance of new shares, or rights offerings during the implementation period of this shareholding reduction plan, the number of shares to be reduced may be adjusted accordingly, but the proportion of reduction will still not exceed 25% of her holdings in the company.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Application for clinical trial of nine-valent HPV vaccine in males has received the drug clinical trial approval letter.
Gelonghui reported on November 18 that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., received a "Clinical Trial Notification" issued by the National Medical Products Administration, agreeing to conduct clinical trials for the nine-valent human papillomavirus vaccine (Escherichia coli) (referred to as the "nine-valent HPV vaccine") for indications in the male population.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): The company currently has no plans to produce the non-segmented HPV vaccine.
Gelonghui November 7th | Beijing Wantai Biological Pharmacy Enterprise (603392.SH) stated on the interactive platform that the company has no plans for segmented production of the nine-valent HPV vaccine.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): The second-phase expansion project of the nine-valent cervical cancer vaccine is progressing as planned, with the main equipment procurement and workshop purification renovation completed.
Gelonghui November 7th | Beijing Wantai Biological Pharmacy Enterprise (603392.SH) stated on the interactive platform that the Phase II expansion project of the nine-valent cervical cancer vaccine is progressing as planned. The main equipment procurement and workshop purification renovation have been completed, and equipment commissioning and validation are underway. In addition to the flagship product, the nine-valent HPV vaccine, other research and development projects of the company are progressing orderly.
Wantai Biotech 2024 Third Quarter Report
IVD sector growth cannot hide the decline in performance. Q0.03 million Tai Biological net profit plummeted more than 90%. | Interpretations
①Affected by market adjustments, government centralized procurement, etc., beijing wantai biological pharmacy enterprise's biological vaccine sector continues to drag down the company's performance. ② The company's diagnostic sector business has grown, and the chemiluminescence product line maintained rapid double-digit growth compared to the same period last year. ③ With factors such as increased investment in industrialization of the nine-valent HPV vaccine, beijing wantai biological pharmacy enterprise's revenue and net profit attributable to the parent company decreased significantly in the first three quarters.
102884128 : getting disappointed with this counter. every day drop.